R-Biopharm Neugen Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
as on 21-12-2024
- Paid Up Capital ₹ 7.83 M
as on 21-12-2024
- Company Age 27 Year, 8 Months
- Last Filing with ROC 31 Dec 2023
- Open Charges ₹ 1.19 Cr
as on 21-12-2024
- Revenue -16.07%
(FY 2022)
- Profit 124.90%
(FY 2022)
- Ebitda -22.93%
(FY 2022)
- Net Worth 3.65%
(FY 2022)
- Total Assets -16.05%
(FY 2022)
About R-Biopharm Neugen
The Corporate was formerly known as Harmony Hi-Tech (Madras) Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2023. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 7.83 M.
The company currently has active open charges totaling ₹1.19 Cr.
Christian Dreher and Shivani Desai serve as directors at the Company.
- CIN/LLPIN
U74220TG1997PTC098579
- Company No.
098579
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 1997
- Date of AGM
21 Jun 2024
- Date of Balance Sheet
31 Dec 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does R-Biopharm Neugen Private Limited offer?
R-Biopharm Neugen Private Limited offers a wide range of products and services, including Medical Consultants & Clinics, Medical Consultancy Services, Medical Surgery & Treatment Centres, Medical Treatment Services, Material Testing Labs & Services, Testing Services.
Who are the key members and board of directors at R-Biopharm Neugen?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivani Desai  | Director | 04-Mar-2021 | Current |
Christian Dreher  | Director | 24-Oct-2013 | Current |
Financial Performance of R-Biopharm Neugen.
R-Biopharm Neugen Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 16.07% decrease. The company also saw a substantial improvement in profitability, with a 124.9% increase in profit. The company's net worth moved up by a moderate rise of 3.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R-Biopharm Neugen?
In 2022, R-Biopharm Neugen had a promoter holding of 100.00%. The company had 2 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trilogy Analytical Laboratory Private LimitedActive 9 years 9 monthsShivani Desai is a mutual person
- Chromogenic Life Sciences (India) Private LimitedActive 14 years 9 days
Shivani Desai is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 May 2020 | ₹1.00 M | Open |
Corporate Bank Creation Date: 18 Oct 2012 | ₹1.09 Cr | Open |
How Many Employees Work at R-Biopharm Neugen?
R-Biopharm Neugen has a workforce of 26 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R-Biopharm Neugen, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R-Biopharm Neugen's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
